Previous 10 | Next 10 |
home / stock / mnpr / mnpr articles
Monopar Therapeutics Inc (NASDAQ:MNPR) shares jumped during the trading session on Thursday on a strong volume session volume of 16.179 millio...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping around 300 points on Thursday. The Dow traded up 0.67% to 38,87...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 200 points on Tuesday. The Dow traded down 0.18% to 38,5...
Monopar Therapeutics Inc (NASDAQ:MNPR) shares jumped over 100% during the trading on Tuesday on a strong volume session volume of 3.94 million...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1.5% on Tuesday. The Dow traded down 0.35% to 38,494.51 w...
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Do...
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. Edible Garden posted a quarterly loss of 69 cen...
StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday. StoneCo p...
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The com...
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead...